Clinical Trial DataEnlivex has already reported positive interim three- and six-month efficacy data for the first 12 patients treated in this Phase 1 stage, with statistically significant improvements in all key efficacy endpoints and no safety issues.
Clinical Trial ProgressEnrollment completed in Phase 2 program.
Intellectual PropertyChinese patent claims allowed, covering Allocetra application in treatment of osteoarthritis, providing added intellectual property protection in China through at least 2040.